Navigation Links
Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
Date:11/10/2011

WARRENDALE, Pa., Nov. 10, 2011 /PRNewswire/ -- Bayer HealthCare's affiliate MEDRAD, Inc. today announced that five-year data from the THUNDER trial* demonstrated a 59 percent relative reduction in target lesion revascularization (TLR) rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance® drug eluting balloon with Paccocath® technology compared to standard balloon angioplasty (POBA). Additionally, for patients requiring TLR, the average time to revascularization before TLR was extended by 448 days in patients treated with the Cotavance catheter, which is available in Europe, but not yet approved in the U.S. MEDRAD is currently moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

The data were presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco as part of a TCT-sponsored symposium titled, "Drug-Coated Balloons: Clinical Data and Applications."

"These data with Bayer HealthCare's Paccocath technology represent the only five-year clinical TLR outcomes in comparison to standard balloons," said Prof. Dr. med. Gunnar Tepe of Klinikum Rosenheim in Rosenheim, Germany, principal investigator of THUNDER. "The results demonstrate clear long-term benefits for patients with the Cotavance paclitaxel eluting balloon for reducing the number of TLR procedures and extending the time before a revascularization might be needed in PAD patients." Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, who presented the data at the TCT symposium, added, "Beginning as early as the first year and continuing through year five, a consistent 30 to 40 percent improvement was seen with the Cotavance catheter in avoiding TLR. TCT was an excellent venue to share these ground-breaking data."

D
'/>"/>

SOURCE Bayer HealthCare-MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
2. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
5. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
8. Neptune Products to be commercialized by BAYER HealthCare
9. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
10. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
11. Bayer CropScience Announces Investment of $25 Million for Institute Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2
... (Nasdaq: NKTR ) announced today that Bharatt ... Operating Officer and Head of the,PEGylation Business Unit. ... the PEGylation Business Unit, including research,and manufacturing, as ... also,serve as Chairman of Nektar India Pvt., Ltd. ...
... 22 Edwards Lifesciences,Corporation (NYSE: EW ... of heart valves,today announced the opening of ... North Crescent, Singapore. The state-of-the-art facility produces,Edwards, ... also serves as the headquarters for Edwards, ...
... Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: ... CDX-110, being developed for the treatment of Glioblastoma,Multiforme ... presentation at the 44th,Annual Meeting of the American ... be held at McCormick Place in Chicago from ...
Cached Biology Technology:Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3Edwards Lifesciences Opens New Singapore Heart Valve Facility 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2
... Abroad ReportedWALL, N.J., Jan. 19 BIO-key International, ... finger-based biometric identification and wireless public safety solutions, ... the media on its fingerprint biometrics identification solutions ... 8th edition of This Week in Consumer ...
... latest American Chemical Society (ACS) Weekly PressPac from the Office ... journals and Chemical & Engineering News . Please credit ... source for this information. ARTICLE #1 FOR IMMEDIATE RELEASE ... , Analytical Chemistry In a macabre discovery ...
... SHORES, Calif., Jan. 14 Communication Intelligence Corporation ... leading supplier of electronic signature solutions for business ... recognized leader** in biometric signature verification will be ... an independent technology and market research company that ...
Cached Biology News:BIO-key(R) Fingerprint Biometrics Media Spotlights 2BIO-key(R) Fingerprint Biometrics Media Spotlights 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 2American Chemical Society's weekly PressPac -- Jan. 14, 2009 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 4American Chemical Society's weekly PressPac -- Jan. 14, 2009 5American Chemical Society's weekly PressPac -- Jan. 14, 2009 6CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 2CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 3CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 4
...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
... Cells and TriEx Insect Cell Medium are ... constructs. This cell/medium combination has been selected ... high protein expression levels observed specifically with ... note that our Ready-Plaque Sf9 Cells and ...
...
Biology Products: